hrp 102 has been researched along with trisequens in 2 studies
| Studies (hrp 102) | Trials (hrp 102) | Recent Studies (post-2010) (hrp 102) | Studies (trisequens) | Trials (trisequens) | Recent Studies (post-2010) (trisequens) |
|---|---|---|---|---|---|
| 33 | 19 | 8 | 56 | 35 | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cacciatore, B; Hasselblatt, R; Nieminen, MS; Paakkari, I; Tikkanen, MI; Toivonen, J; Ylikorkala, O | 1 |
| Strandberg, TE; Tikkanen, MJ; Ylikorkala, O | 1 |
2 trial(s) available for hrp 102 and trisequens
| Article | Year |
|---|---|
Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women.
Topics: Administration, Cutaneous; Administration, Oral; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Drug Combinations; Estradiol; Estriol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Norethindrone; Prospective Studies; Statistics, Nonparametric | 2001 |
Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women.
Topics: Administration, Cutaneous; Administration, Oral; Age Factors; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Contraceptives, Oral, Combined; Drug Combinations; Estradiol; Estriol; Estrogen Replacement Therapy; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Middle Aged; Norethindrone; Reference Values; Risk Factors | 2003 |